H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Soleno Therapeutics today and set a price target of $110.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ram Selvaraju has given his Buy rating due to a combination of factors that highlight Soleno Therapeutics’ strong financial performance and promising market potential. The company reported impressive sales figures for the third quarter of 2025, significantly exceeding expectations with $66 million in revenue compared to the forecasted $41.2 million. This robust performance led to Soleno achieving profitability ahead of schedule, and the company is expected to maintain a positive cash flow moving forward, driven by the demand for their product, VYKAT XR.
Additionally, the analyst notes that the market penetration for VYKAT XR is currently estimated at only 25% of the U.S. market, indicating substantial room for growth. Despite certain limitations and contraindications for specific patient groups, the overall risk to forecasts is considered minimal. The company also holds a strong financial position with a substantial cash reserve, which could support future expansion through mergers, acquisitions, or licensing opportunities. These factors contribute to the reiterated Buy rating and a 12-month price target of $110.
In another report released on November 5, LifeSci Capital also maintained a Buy rating on the stock with a $110.00 price target.